149 related articles for article (PubMed ID: 37872022)
1. Bivalirudin versus unfractionated heparin in patients with myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized controlled trials.
Al-Abdouh A; Mhanna M; Jabri A; Madanat L; Alhuneafat L; Mostafa MR; Kundu A; Gupta V
Cardiovasc Revasc Med; 2024 Apr; 61():52-61. PubMed ID: 37872022
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
3. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Zhang S; Gao W; Li H; Zou M; Sun S; Ba Y; Liu Y; Cheng G
Int J Cardiol; 2016 Apr; 209():87-95. PubMed ID: 26882192
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin versus heparin in women undergoing percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials.
Saad M; Nairooz R; Rashed A; Abdelaziz HK; Mentias A; Abbott JD
Cardiovasc Revasc Med; 2017 Sep; 18(6):418-424. PubMed ID: 28291727
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials.
Meng S; Xu J; Guo L; Huang R
Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149
[TBL] [Abstract][Full Text] [Related]
7. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials.
Shah R; Matin K; Rogers KC; Rao SV
Catheter Cardiovasc Interv; 2017 Aug; 90(2):196-204. PubMed ID: 27862911
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention.
Shah R; Jovin IS; Chaudhry A; Haji SA; Askari R; Dennis MM; Berzingi C; Rao SV
Catheter Cardiovasc Interv; 2019 Feb; 93(2):241-247. PubMed ID: 30269393
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Liu XQ; Luo XD; Wu YQ
Medicine (Baltimore); 2020 Feb; 99(6):e19064. PubMed ID: 32028428
[TBL] [Abstract][Full Text] [Related]
10. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.
Bikdeli B; Erlinge D; Valgimigli M; Kastrati A; Han Y; Steg PG; Stables RH; Mehran R; James SK; Frigoli E; Goldstein P; Li Y; Shahzad A; Schüpke S; Mehdipoor G; Chen S; Redfors B; Crowley A; Zhou Z; Stone GW
Circulation; 2023 Oct; 148(16):1207-1219. PubMed ID: 37746717
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.
Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K
Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin versus unfractionated heparin for percutaneous coronary intervention with radial access: A meta-analysis of randomized trials.
Mahmoud AN; Elgendy IY
Int J Cardiol; 2016 Aug; 216():128-32. PubMed ID: 27153137
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
[TBL] [Abstract][Full Text] [Related]
15. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study.
Garcia-Garcia HM; Adamo M; Soud M; Yacob O; Picchi A; Sardella G; Frigoli E; Limbruno U; Rigattieri S; Diletti R; Boccuzzi G; Zimarino M; Contarini M; Russo F; Calabrò P; Andò G; Varbella F; Garducci S; Palmieri C; Briguori C; Karagiannis A; Valgimigli M
Catheter Cardiovasc Interv; 2020 Nov; 96(6):1156-1171. PubMed ID: 31883294
[TBL] [Abstract][Full Text] [Related]
16. Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis.
Fahrni G; Wolfrum M; De Maria GL; Banning AP; Benedetto U; Kharbanda RK
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27451466
[TBL] [Abstract][Full Text] [Related]
17. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505
[TBL] [Abstract][Full Text] [Related]
19. Effect of Post-Primary Percutaneous Coronary Intervention Bivalirudin Infusion on Acute Stent Thrombosis: Meta-Analysis of Randomized Controlled Trials.
Shah R; Rogers KC; Ahmed AJ; King BJ; Rao SV
JACC Cardiovasc Interv; 2016 Jul; 9(13):1313-20. PubMed ID: 27318846
[TBL] [Abstract][Full Text] [Related]
20. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions.
Grajek S; Michalak M; Gwizdała A; Araszkiewicz A; Grygier M; Hiczkiewicz J; Lesiak M
Kardiol Pol; 2018; 76(4):740-749. PubMed ID: 29350380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
